A Phase I Open Label Study Of Panobinostat In Combination With Lenalidomide, Bortezomib, And Dexamethasone In Patients With Relapsed And Relapsed/Refractory Multiple Myeloma
Latest Information Update: 07 Sep 2021
Price :
$35 *
At a glance
- Drugs Panobinostat (Primary) ; Bortezomib; Dexamethasone; Lenalidomide
- Indications Multiple myeloma
- Focus Adverse reactions
- Acronyms PanRVD
- 03 Sep 2021 Status changed from active, no longer recruiting to completed.
- 21 Jun 2020 Results presented at the 25th Congress of the European Haematology Association
- 31 Jan 2020 Planned End Date changed from 1 Dec 2019 to 1 Dec 2021.